Drug Profile
SAR 411298
Alternative Names: SAR411298Latest Information Update: 02 May 2012
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer pain
Most Recent Events
- 31 Mar 2012 Discontinued - Phase-I for Cancer pain in Europe (unspecified route)
- 09 Feb 2011 Phase-I clinical trials in Cancer pain in Europe (unspecified route)